GlassScriptPhysician profile
Ramona Bacon
NPI 1366865875
$1,912.20
in general payments reported to CMS, 2019-2025
22 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $723 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,132 · Education: $780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.02 |
| Education | $780.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $306.31 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $245.80 | 2024-2025 | Enhertu, Vanflyta |
| Janssen Biotech, INC. | $204.91 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Sobi, INC | $194.89 | 2025 | |
| Gilead Sciences, INC. | $130.32 | 2024-2025 | Trodelvy |
| Seagen INC. | $99.99 | 2025 | |
| Celgene Corporation | $98.03 | 2024-2025 | Reblozyl |
| Coherus Oncology, INC. | $86.35 | 2025 | Loqtorzi |
| Pfizer INC. | $76.74 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $74.81 | 2024-2025 | Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $62.76 | 2025 | Iclusig |
| Merck Sharp & Dohme LLC | $60.07 | 2024-2025 | Keytruda |
| Incyte Corporation | $50.58 | 2025 | Jakafi |
| Pharmacosmos Therapeutics INC. | $38.38 | 2024 | Cosela |
| Abbvie INC. | $33.60 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.41 | 2024-2025 | Xtandi |
| Genentech USA, INC. | $24.10 | 2024 | Gazyva, Venclexta |
| Glaxosmithkline, LLC. | $22.32 | 2025 | Ojjaara |
| Stemline Therapeutics INC. | $20.48 | 2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $18.53 | 2025 | Pyrukynd |
| Servier Pharmaceuticals LLC | $17.18 | 2024 | |
| Caris Mpi, INC. | $13.64 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramona Bacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.